Treatment of Indigestion with the Unani Medicine Jawarish-e-Javed.

Clinical Validation Study of Unani Pharmacopeial Formulation Jawarish-e-Javed in Zof-e Meda (Functional dyspepsia) - NILL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099616

Enrollment

110

Registered

2025-12-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K30- Functional dyspepsia

Interventions

Intervention1: Jawarish-e- Javed: 5 gm BD taken orally with water after meal for 6 weeks. Control Intervention1: Nill : Nill

Eligibility

Inclusion criteria

Inclusion criteria: 1-Patients of either sex in the age group of 18-65 years. 2-Patients meeting the Rome IV Criteria (Postprandial Distress Syndrome) as under 3-Patients with Mild to moderate dyspepsia as defined by a score ranging between 1-15 as per the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ)

Exclusion criteria

Exclusion criteria: 1- Patients with Severe dyspepsia as defined by a score ranging more then 15 as per the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ). 2- Patients showing alarm symptoms (weight loss, anemia, hematemesis, melena, dysphagia, palpable abdominal mass). 3- Patients with systemic illness e.g.Diabetes/Hypertension/Tuberculosis/Anemia. 4- Known case of Gastric peptic ulcer with H. pylori Infection or reflux esophagitis within the past 6 months were excluded 5- Known case of gastrointestinal surgery. 6- Known cases of Intra-abdominal malignancy (e.g. stomach/Pancreas/Liver or Gastricleiomyoma/Leiomyosarcoma/Malignant Lymphoma) 7- Patient requiring long term therapy e.g. Hepatic, Renal or Cardiac Ailments. 8- History of surgery related with the gastrointestinal tract more than six months 9- Pregnant and lactating females.

Design outcomes

Primary

Measure	Time frame
Improvement in the signs and symptoms of Zof-e Meda (Functional dyspepsia). Which will be assessed on the basis of Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ).Timepoint: At baseline and every two weeks during the treatment period (i.e., at 0, 2nd, 4th, and 6th week).	—

Secondary

Measure	Time frame
Haematological and biochemical investigations for safety assessment i.e.,Haemogram, LFT, KFT, stool and Urine R/M.Timepoint: At baseline and at the end of treatment.( i.e., 0 and 6th week)	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

younismunshi@gmail.com09419086700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026